van Akkooi, Alexander C. J. and Haferkamp, Sebastian and Papa, Sophie and Franke, Viola and Pinter, Andreas and Weishaupt, Carsten and Huber, Margit A. and Loquai, Carmen and Richtig, Erika and Gokani, Priya and Ohrling, Katarina and Louie, Karly S. and Mohr, Peter (2021) A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. ADVANCES IN THERAPY, 38. pp. 1245-1262. ISSN 0741-238X, 1865-8652
Full text not available from this repository. (Request a copy)Abstract
Introduction Talimogene laherparepvec (T-VEC; IMLYGIC (R), Amgen Inc.) is an oncolytic immunotherapy approved in Europe for the treatment of unresectable metastatic melanoma (stage IIIB-IVM1a). This study characterised real-world use of T-VEC in four European countries. Methods: Data on demographics, treatment pattern, safety, and clinical effectiveness were examined in a retrospective chart review of patients with stage IIIB-IVM1a unresectable melanoma treated with T-VEC in surgical (the Netherlands) and medical (Austria, Germany, UK) oncology settings. Results: Overall, 66 patients were included (the Netherlands: n = 31; Austria, Germany, UK: n = 35). The median age was 69 years and 59.1% were female. At the time of T-VEC initiation, 47 patients (71.2%) had stage IIIB/C disease; of these, 30 were from the Netherlands. Although 72.7% patients overall received T-VEC as first-line therapy, this was higher in the Netherlands than the other countries (93.5% vs 54.3%). Of the 47 patients who discontinued T-VEC, 26 (55.3%) had no remaining injectable lesions (potentially indicating complete response); 20/26 of these patients were from the Netherlands. One patient discontinued T-VEC due to toxicity. Conclusion: This study is the first comprehensive multinational evaluation of the use of T-VEC to treat unresectable stage IIIB/C-IVM1a melanoma in real-world clinical practice in Europe. The differences between European countries were apparent, with physicians in the Netherlands using T-VEC in patients with earlier advanced disease stage and in the first-line setting compared with other countries.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HERPES-SIMPLEX-VIRUS; T-CELL; Immunotherapy; Injectable; Lesion; Melanoma; Oncolytic; Real-world study; Skin cancer; T-VEC; Talimogene laherparepvec; Tumour |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 22 Apr 2021 05:30 |
| Last Modified: | 22 Apr 2021 05:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43088 |
Actions (login required)
 |
View Item |
